These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32058159)

  • 61. Effect of early or late blood sampling on thyrotropin releasing hormone stimulation test results in horses.
    Thane K; Uricchio C; Frank N
    J Vet Intern Med; 2022 Mar; 36(2):770-777. PubMed ID: 35049089
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Thyroid Hormone and Thyrotropin Concentrations and Responses to Thyrotropin-Stimulating Hormone in Horses with PPID Compared with Age-Matched Normal Horses.
    Breuhaus BA
    J Equine Vet Sci; 2019 Apr; 75():35-40. PubMed ID: 31002090
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
    Gehlen H; Fisch J; Merle R; Trachsel DS
    J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of body condition, body weight and adiposity on inflammatory cytokine responses in old horses.
    Adams AA; Katepalli MP; Kohler K; Reedy SE; Stilz JP; Vick MM; Fitzgerald BP; Lawrence LM; Horohov DW
    Vet Immunol Immunopathol; 2009 Feb; 127(3-4):286-94. PubMed ID: 19097648
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessment of tissue-specific cortisol activity with regard to degeneration of the suspensory ligaments in horses with pituitary pars intermedia dysfunction.
    Hofberger SC; Gauff F; Thaller D; Morgan R; Keen JA; Licka TF
    Am J Vet Res; 2018 Feb; 79(2):199-210. PubMed ID: 29359976
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neutrophil function in healthy aged horses and horses with pituitary dysfunction.
    McFarlane D; Hill K; Anton J
    Vet Immunol Immunopathol; 2015 Jun; 165(3-4):99-106. PubMed ID: 25962580
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
    Rendle DI; Doran G; Ireland J; Edwards S
    Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fecal egg counts after anthelmintic administration to aged horses and horses with pituitary pars intermedia dysfunction.
    McFarlane D; Hale GM; Johnson EM; Maxwell LK
    J Am Vet Med Assoc; 2010 Feb; 236(3):330-4. PubMed ID: 20113248
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of two methods for measurement of equine adrenocorticotropin.
    Banse HE; Schultz N; McCue M; Geor R; McFarlane D
    J Vet Diagn Invest; 2018 Mar; 30(2):233-237. PubMed ID: 29284383
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction.
    Carmalt JL; Mortazavi S; McOnie RC; Allen AL; Unniappan S
    PLoS One; 2018; 13(1):e0190796. PubMed ID: 29309431
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Circadian and circannual rhythms of cortisol, ACTH, and α-melanocyte-stimulating hormone in healthy horses.
    Cordero M; Brorsen BW; McFarlane D
    Domest Anim Endocrinol; 2012 Nov; 43(4):317-24. PubMed ID: 22717182
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Agreement in histologic assessments of the pituitary pars intermedia in aged horses.
    McFarlane D; Miller LM; Craig LE; Dybdal NO; Habecker PL; Miller MA; Patterson JS; Cribb AE
    Am J Vet Res; 2005 Dec; 66(12):2055-9. PubMed ID: 16379646
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Age-related Qualitative Histological and Quantitative Stereological Changes in the Equine Pituitary.
    Leitenbacher J; Herbach N
    J Comp Pathol; 2016; 154(2-3):215-24. PubMed ID: 26810844
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Venipuncture does not affect adrenocorticotropic hormone concentration in horses.
    Fouché N; van der Kolk JH; Bruckmaier RM; Luz I; Foerster G; Gerber V
    Vet Rec; 2015 Sep; 177(9):223. PubMed ID: 26246396
    [No Abstract]   [Full Text] [Related]  

  • 75. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.
    McFarlane D
    Ageing Res Rev; 2007 May; 6(1):54-63. PubMed ID: 17374512
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Development and Evaluation of a Muscle Atrophy Scoring System (MASS) for Horses.
    Herbst AC; Johnson MG; Gammons H; Reedy SE; Urschel KL; Harris PA; Adams AA
    J Equine Vet Sci; 2022 Mar; 110():103771. PubMed ID: 34973594
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pituitary pars intermedia dysfunction (Equine Cushing's disease) in an onager (Equus hemionus onager).
    Peel AJ; Bouts T; Flach E; Rivers S; Routh A
    J Zoo Wildl Med; 2009 Dec; 40(4):773-80. PubMed ID: 20063825
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Endocrine Disorders of the Equine Athlete.
    Frank N
    Vet Clin North Am Equine Pract; 2018 Aug; 34(2):299-312. PubMed ID: 29857965
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of the sensitivity and specificity of basal plasma adrenocorticotrophic hormone concentration for diagnosing pituitary pars intermedia dysfunction in horses: A systematic review.
    Tatum RC; McGowan CM; Ireland JL
    Vet J; 2021 Sep; 275():105695. PubMed ID: 34099343
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The accuracy of ACTH as a biomarker for pituitary pars intermedia dysfunction in horses: A systematic review and meta-analysis.
    Meyer JC; Hunyadi LM; Ordóñez-Mena JM
    Equine Vet J; 2022 May; 54(3):457-466. PubMed ID: 34428330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.